EGFR and heart failure: Prior studies in patients with NSCLC, without regard to EGFR mutational status, had illustrated a high rate of cardiovascular comorbidity in this population (approximately 20 to 36 %, depending on the definitions used) [26–29], as well as increased cardiac failure rates in chemotherapy-treated versus -untreated patients [30, 31].